Last reviewed · How we verify
NCT00388076
Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
Phase 1 trial testing Pazopanib in Neoplasms, Breast in 86 participants. Completed in 21 July 2009.
21 July 2009
Quick facts
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 86 |
| Start date | 28 April 2006 |
| Primary completion | 21 July 2009 |
| Estimated completion | 21 July 2009 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Pazopanib — full drug profile →
- Lapatinib (LAPATINIB) — full drug profile →
- paclitaxel — full drug profile →
- carboplatin (Carboplatin) — full drug profile →
Conditions studied
- Neoplasms, Breast — all drugs for Neoplasms, Breast →
Sponsor
GlaxoSmithKline — full company profile →
Who can join
18 and older, any sex, with Neoplasms, Breast. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pazopanib will be given with TAXOL in one part, in another part pazopanib will be given with TAXOL and PARAPLATIN, and in a third part pazopanib will be given with TAXOL and lapatinib (patients separated in each part). Toxicity monitoring will enable us to find the largest dose of pazopanib daily that can be safely given in combination with the chemotherapy agents TAXOL and PARAPLATIN, and with lapatinib, as well as what side effects are likely to manifest when these agents are given together and whether the combination of pazopanib with chemotherapy, helps to treat different types of cancer. Another objective is to find out how much pazopanib, TAXOL, PARAPLATIN and lapatinib are in the blood at specific times after the agents are given. Collecting the blood samples requires that the patients remain in the vicinity of the clinic overnight on 2 occasions.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.
Tan AR, Dowlati A, Jones SF, Infante JR, et al · · 2010 · cited 39× · PMID 21147873 · DOI 10.1634/theoncologist.2010-0095 -
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Tan AR, Dowlati A, Stein MN, Jones SF, et al · · 2014 · cited 13× · PMID 24800949 · DOI 10.1038/bjc.2014.233
Verify or expand the search:
- PubMed search for NCT00388076
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pazopanib
Trials testing the same drug.
- NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
- NCT07087158 — A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma · Phase 2 · not yet recruiting
- NCT04199026 — Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sa · NA · recruiting
- NCT03850730 — Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia · Phase 1, PHASE2 · unknown
- NCT05432791 — Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped W · Phase 2, PHASE3 · active not recruiting
Other recruiting trials for Neoplasms, Breast
Currently open trials in the same condition.
- NCT06819215 — Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT04915755 — Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HE · Phase 3 · active not recruiting
Other GlaxoSmithKline trials
Trials by the same sponsor.
- NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
- NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
- NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00388076 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
- Last refreshed: 17 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00388076.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing